Ligand Pharmaceuticals Incorporated LGND announces the signing of a
license agreement with Ethicor Pharma Ltd. for the manufacture and
distribution of the oral formulation of lasofoxifene in the European Economic
Area, Switzerland and the Indian Subcontinent. Under the terms of the
agreement, Ligand is entitled to receive potential sales milestones and a
double digit royalty on future net sales.
Ethicor plans to supply oral lasofoxifene as an unlicensed medicinal product,
which may be requested by healthcare professionals to meet the clinical needs
of patients when authorized medicines are unsuitable or contraindicated. In
the European Union, there are approximately 37 million women suffering with
osteoporosis.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in